{
  "trial_id": "NCT03521921",
  "overall_assessment": "likely_eligible",
  "inclusion": [
    {
      "criterion": "retrospective enrolments are allowed",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "follow-up visit will be performed at 30 days, 1 year and up to 5 years after the procedure",
      "label": "met",
      "evidence": "none"
    },
    {
      "criterion": "patients who are eligible for Mitraclip device according to current national and international guidelines (and their future revisions) and per investigator evaluation",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "patients who are willing and capable of providing informed consent, participating in all Follow-ups associated with this clinical investigation at an approved clinical investigational center",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "symptomatic severe (4+) MR, or 3+ MR and NYHA > II",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "mitral valve anatomy should be suitable for MitraClip",
      "label": "met",
      "evidence": "quote"
    },
    {
      "criterion": "signed (by subject or legal representative) and dated approved subject informed consent form prior to any study related data collection",
      "label": "unknown",
      "evidence": "none"
    }
  ],
  "exclusion": [
    {
      "criterion": "valve anatomy is unsuitable for MitraClip therapy as per the indication in the Mitraclip IFU",
      "label": "not_met",
      "evidence": "quote"
    },
    {
      "criterion": "currently participating in the study of an investigational drug or device",
      "label": "unknown",
      "evidence": "none"
    },
    {
      "criterion": "the subject is unable or not willing to complete follow-up visits and examination for the duration of the study",
      "label": "not_met",
      "evidence": "quote"
    }
  ],
  "notes": "Patient has Marfan's syndrome with severe mitral valve prolapse and regurgitation, but remains symptomatic and is prepared to undergo surgery. EF of 65% on TTE.",
  "_meta": {
    "topic_id": "12",
    "trial_id": "NCT03521921",
    "model": "llama3.1:8b",
    "run_tag": "llama31_8b_full_top100",
    "top_k": 100
  }
}